We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to the contract, T-E Meds will receive a signing and licensing fee of NT$270 million (approximately USD 8.5 million) for granting the commercialization rights of the TE-1146 drug in Taiwan, Southeast Asia, New Zealand and the Australia to Orient EuroPharma.
This strategic partnership marks a significant milestone in our mission to revolutionize cancer treatment. As we continue to develop our proprietary Multi-Arm Linkers and bioconjugation technologies, we remain committed to advancing our pipeline and exploring new collaboration opportunities.
We look forward to working closely with Orient EuroPharma to bring this innovative therapy to patients in need. Together, we are shaping the future of cancer treatment.
News website link: